Using video-based training for button-free auto-injection of subcutaneous methotrexate: A pilot study

Dawn Homer

Community Rheumatology Service, Modality Partnership, Enki Medical Practice, Handsworth, Birmingham, UK

Correspondence
Dawn Homer, Community Rheumatology Service, Modality Partnership, Enki Medical Practice, Handsworth, Birmingham, B19 1BP, UK.
Email: dhomer@nhs.net

Funding information
Nordic Pharma; Nordic Pharma UK Ltd; Clark Health Communications

KEYWORDS: rheumatoid arthritis, patient education, self-management

1 | INTRODUCTION

Methotrexate (MTX) is the treatment of choice for immune-mediated joint and skin disorders such as rheumatoid arthritis and psoriatic arthritis (Gossec et al., 2016; Lopez-Olivo et al., 2014; Smolen et al., 2010, Vena, Cassano, & Lannone, 2018). It acts at multiple points in the inflammatory pathway to improve clinical symptoms and disease control, and treatment adherence is essential for the maintenance of this control (Bello, Perkins, Jay, & Efthimiou, 2017). Subcutaneous (SC) administration has contributed substantially to improving adherence to MTX (Scott, Claydon, & Ellis, 2014). When compared with oral dosing, it offers greater clinical efficacy in both early and long-term disease, and a delay in progression to biological therapy (Bello et al., 2017). It also offers more flexible dosing and has greater tolerability, particularly with respect to the gastrointestinal toxicity of oral formulations (Bianchi, Caporali, Todoerti, & Mattana, 2016). The availability of prefilled delivery systems has made the SC injection process even more straightforward, and enhanced the ease and safety of MTX administration (Royal College of Nursing, 2016).

Studies show that self-injection improves patient self-esteem and quality of life, while reducing healthcare costs when compared with nurse-administered injection (Berteau et al., 2010; Lugaresi et al., 2008). For it to be successful, patients need to be confident in their use of the injection device, possess the manual dexterity for successful operation and be able to overcome any concerns regarding the safe delivery of MTX. Over the last decade, a number of different devices have been developed for self-injection of SC MTX. Studies show that patients with rheumatoid arthritis prefer auto-injector devices to prefilled syringes, reporting them to be more convenient, easier to use and less painful (Demary et al., 2014; Pachon, Kivitz, Heuer, & Pichlmeyer, 2014; Saraux, Hudry, Zinovieva, & SELF-I Investigators group, 2019; Thakur, Biberger, Handrich, & Farouk Rezk, 2016).

However, the use of auto-injection devices is not without its issues. Devices vary in terms of ease and mode of use, and one-to-one instruction to ensure safe and effective administration and disposal can take up valuable time in the rheumatology clinic (Homer, Nightingale, & Jobanputra, 2009). Local contract variations and pharmacy stock issues can expose patients to changes in device prescribing and availability, and require nurses to train patients in more than one auto-injection device. The increasing availability of biological disease-modifying antirheumatic drugs (bDMARDs) delivered by SC injection adds to this burden. In our practice, we use FP10 prescribing (i.e., prescriptions that are routinely issued in primary care by a general practitioner or nonmedical prescriber), and the local community pharmacist orders in the device. As a result, we can manage the devices being used, and the patients avoid any overstock issues.

New and experienced injectors alike are likely to require MTX SC self-injection training. One of the ways to address the issue of nurse resource and associated healthcare costs is to look at the use of devices that can simplify the auto-injection process and reduce the amount of training time required. The present pilot study looked at whether patients could be instructed to use a MTX prefilled, button-free, auto-injector pen with a double-click mechanism for SC injection (NORDIMET®, Nordic Group BV, The Netherlands) via video training instead of nurse demonstration. It also looked at whether this mode of training affected patient confidence in self-injection and satisfaction with the device. A secondary objective of the study was to assess...
levels of satisfaction with the button-free device across a number of different criteria and compare it with the patient’s previous device.

2 | METHODS

All patients with a clinical diagnosis of rheumatoid arthritis or psoriatic arthritis (or other inflammatory condition) for which they were currently administering SC MTX using a button-activated pen device (n = 33) were invited to change to a button-free, auto-injector by letter. Those choosing to switch were given the choice of self-training using a 2-min online video (Nordic Pharma UK Ltd, 2019) or receiving standard one-to-one instruction from a rheumatology nurse in the clinic.

Patients were contacted approximately 4 weeks after the switch and invited to participate in a 10-min telephone questionnaire (18 items) designed to evaluate their experience of using the button-free auto-injector, and to be completed by the author during a 10-min telephone interview with each individual patient.

Thirty-three patients were invited to change to the button-free auto-injector. Twenty-two (67%) patients responded initially, and 19 completed the study (three patients failed to complete the questionnaire).

3.1 | Choice of instruction when switching devices

Of the 19 who completed the study, 14 (73.7%) chose to self-train and five (26.3%) chose an appointment with their rheumatology nurse. Of those patients choosing to self-train, 11 used the video and three were confident to proceed without any instruction, based on their use of similar devices or willingness to use printed support materials.
3.2 | Patient profile

The profile of the study participants choosing to switch devices is summarized in Table 1. The majority were female, aged under 60 years, with English as their main language. The majority had rheumatoid arthritis and had been diagnosed within the last 10 years. Most had been self-injecting MTX with an auto-injection device for at least 5 years. There were no discernible differences regarding demographics, disease profile or device use when comparing those patients who chose to self-train via video with those who asked for a nurse visit.

3.3 | Patient confidence and ability to use the button-free auto-injector

Of those patients choosing to self-train (n = 11), 100% tended to agree or strongly agreed that the self-training video provided sufficient instruction on how to use the button-free auto-injector; 91% (n = 10) tended to agree or strongly agreed that they were confident that they could perform self-injection correctly, without help, after watching the video (see Figure 2). Only one patient opting to self-train indicated they would have preferred to receive nurse instruction.

3.4 | Satisfaction with the button-free auto-injector

Approximately 80% (n = 15) of patients overall were satisfied or very satisfied with administering MTX using the button-free auto-injector. Although numbers were small, self-training did not appear to reduce satisfaction with the device: 84.6% of those patients stating that the video was all they needed for instruction and 83.3% of those who were confident in their ability to perform self-injection correctly after viewing the video were satisfied or very satisfied with the device. Three patients discontinued the button-free device: one switched to
oral therapy for reasons unrelated to the device, and two returned to their original device.

The majority of patients switching (85%) were equally or more satisfied with the use of the button-free auto-injector pen compared with their previous device. When looking at specific attributes, patients were equally or more satisfied with the button-free auto-injector when compared with their previous device across all seven criteria (see Figure 3). Comfort in hand, confidence in full dose being given and ease of injection were all attributes prompting greater satisfaction when compared with their previous device in more than 50% of patients. At the postswitch follow-up, 13 patients provided additional comments on the button-free auto-injector that were not covered specifically by the questionnaire (see Figure 4). One patient declared that she was able to self-inject unaided for the first time.

4 | DISCUSSION

The present pilot study is the first to show the potential for patient-driven use of instructional videos to facilitate self-training in the use of an MTX button-free auto-injector device without having a negative impact on the ability to self-inject, confidence in administration or satisfaction with use. More than 80% of those patients who were confident in their ability to perform self-injection correctly after viewing the video were satisfied or very satisfied with the button-free auto-injector device.

These findings have implications for the future training of patients in the use of auto-injection devices for SC MTX. Education regarding the self-injection of MTX is important in promoting the understanding of the risk and benefits of therapy. Some patients may also experience anxiety around self-injection, express concerns around spillage, pain or fear of needles (Saraux et al., 2019). Initial nurse training is therefore essential in providing reassurance. A video is a useful option for instruction in the use of a device, freeing up valuable clinical time that could then be used for the training of patients new to SC MTX.
The use of video training for self-injection is not a new concept but there are few studies assessing its impact and value for SC MTX. A study by Katz and Leung (2015) compared standard nurse-led MTX self-injection education with a 12-min web-based video plus standard teaching on patient confidence with self-injection, patient satisfaction, and knowledge and teaching time. There was no impact on satisfaction with MTX self-injection, and a trend towards a greater knowledge of the procedure.

In the study described here, assuming that all patients would have attended one visit for initial training on self-injection of SC MTX, use of the self-training video reduced the number of nurse visits required in patients familiar with self-injection by 50%, freeing up valuable nurse time. In reality, we estimate there to be an average of 1.5 follow-up visits per switch in our community rheumatology service, as some patients require one visit and others require two, following a change of device. Eleven patients choosing to self-train by video, therefore, creates the potential to save 16.5 nurse visits. If each visit is equivalent to 20 min of nursing time, at a cost of £78 (representing 70% of the national tariff [NHS Improvement, 2019]), there is a potential saving of approximately £1,287. Our study did not quantify the savings in nursing time or costs; these are purely estimates of the potential impact. However, a similar positive effect on nursing time was demonstrated in a study by Saraux et al. (2019). In a comparison of the same button-free auto-injector with a prefilled syringe, the authors reported that the proportion of injections involving healthcare professionals was threefold lower than in the group using the prefilled syringe. In the study by Katz and Leung (2015) described above, use of the video reduced the amount of nurse teaching time by approximately 25%. In this study, one patient regretted their choice of self-training via video, expressing a later preference for a nurse. By contrast, three patients were confident to proceed with using the button-free auto-injector with neither the self-training video nor nurse instruction. Factors that both increase and decrease patient confidence in the use of an alternative device would be useful to explore in further studies.

Three studies have looked at the patient acceptability, usability, and satisfaction of auto-injection devices for self-injection of MTX when compared with prefilled syringes (Demary et al., 2014; Hudry et al., 2017; Saraux et al., 2019). Both Demary et al. (2014) and Saraux et al. (2019) showed a patient preference for the auto-injector with regard to user acceptability and satisfaction. The present study took the evaluation one stage further, by comparing satisfaction with use of button-free and button-activated devices across different attributes. Satisfaction with the button-free auto-injector was high in general and, for the majority of patients, equal or greater when compared with their previous device.

The present study was a single-centre pilot, designed to test the impact of video training on confidence and ability to self-inject MTX when switching to a different device. All postswitch interviews were conducted by the same rheumatology nurse (D.H.), reducing the possibility of interviewer bias, and the detailed questionnaire gathered useful insights that could be used further to develop tools to evaluate the impact of different interventions on nursing time. As with all studies involving questionnaires, the possibility of self-selection bias is a limitation. Single-centre recruitment limits the utility of results across different patient populations, and the lack of data regarding previous auto-injection devices limits comparability with other studies. Moving forward, the inclusion of additional centres and more quantitative assessment of the impact on nursing time will prove useful in generating data about potential cost savings when training patients in the use of MTX self-injection. This information may prove useful when looking at opportunities to streamline device use across MTX and bDMARDs, and may prove to be of interest in many areas of healthcare provision, including pharmacy.

5 | CONCLUSION

This pilot study is the first to show the potential for patient-driven use of instructional videos to facilitate self-training in the use of an MTX button-free auto-injector device without having a negative impact on confidence in administration or satisfaction with use. The benefits of patient choice and nurse resource allocation should, therefore, be considered when making wholesale switches to alternative devices for delivery of the same medication.

ACKNOWLEDGEMENTS

The author would like to thank the patients who took part in the study. Medical writing support was provided by Clark Health Communications and paid for by Nordic Pharma UK Ltd.

CONFLICTS OF INTEREST

The author has worked as a consultant for Bristol Myers Squibb, Janssen-Cilag and Lilly.

ORCID

Dawn Homer https://orcid.org/0000-0002-7624-7080

REFERENCES

Bello, A. E., Perkins, E. L., Jay, R., & Efthimiou, P. (2017). Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatology, 9, 67–79. https://doi.org/10.2147/OARRR.S131668
Berteau, C., Schwarzenbach, F., Donazzolo, Y., Latreille, M., Berube, J., Abry, H., ... Laurent, P. E. (2010). Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers. Patient Preference and Adherence, 4, 379–388.
Bianchi, G., Caporali, R., Toderti, M., & Mattana, P. (2016). Methotrexate and rheumatoid arthritis: Current evidence regarding subcutaneous versus oral routes of administration. Advances in Therapy, 33(3), 369–378. https://doi.org/10.1007/s11632-016-0295-8
Demary, W., Schwenke, H., Rockwitz, K., Kästner, P., Liehbauer, A., Schoo, U., ... Müller-Ladner, U. (2014). Subcutaneously administered methotrexate for rheumatoid arthritis; by prefilled syringes versus...
prefilled pens: patient preference and comparison of the self-injection experience. Patient Preference and Adherence, 8, 1061–1071. https://doi.org/10.2147/PPA.S6411

Gossec, L., Smolen, J. S., Ramiro, S., de Wit, M., Cutole, M., Dougados, M., ... van der Heijde, D. (2016). European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 75, 499–510. https://doi.org/10.1136/annrheumdis-2015-208337

Homer, D., Nightingale, P., & Jobanputra, P. (2009). Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction. Musculoskeletal Care, 7(2), 78–92. https://doi.org/10.1002/msc.141

Hudry, C., Lebrun, A., Moura, B., Zinovieva, E., Backers, O., & Herman-Demars, H. (2017). Evaluation of usability and acceptance of a new autoinjector intended for methotrexate subcutaneous self-administration in the management of rheumatoid arthritis. Rheumatology and Therapy, 4(1), 183–194. https://doi.org/10.1007/s40744-017-0057-3

Katz, S. J., & Leung, S. (2015). Teaching methotrexate self-injection with a web-based video maintains patient care while reducing healthcare resource: A pilot study. Rheumatology International, 35(1), 93–96. https://doi.org/10.1007/s00296-014-3076-1

Lopez-Olivo, M. A., Siddhanamatha, H. R., Shea, B., Tugwell, P., Wells, G. A., & Suarez-Almazor, M. E. (2014). Methotrexate for treating rheumatoid arthritis (Review). Cochrane Database of Systematic Reviews, 6, CD000957. https://doi.org/10.1002/14651858.CD000957.pub2

Lugaresi, A., Durastanti, V., Gasperini, C., Lai, M., Pozzilli, C., Orefice, G., ... CoSa Study Group (2008). Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. Clinical Neuropharmacology, 31, 167–172. https://doi.org/10.1097/wnf.0b013e3181571a8e

NHS Improvement. (2019). National tariff payment system 2017/18 and 2018/19. Retrieved from https://improvement.nhs.uk/resources/national-tariff-1719/#h2-tariff-documents

Nordic Pharma UK Ltd (2019). How to use [video file]. Retrieved from https://www.nordimet.co.uk/patient/ Accessed online 17th July 2019.

Pachon, J. A., Kivitz, A. J., Heuer, K. U., & Pichlmeyer, U. (2014). Assessing usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis. SAGE Open Medicine, 2. https://doi.org/10.1177/2050312114564241

Royal College of Nursing (2016). Administering subcutaneous methotrexate for inflammatory arthritis. RCN guidance (3rd ed.). London: Royal College of Nursing. Retrieved from https://www.rcn.org.uk/professional-development/publications/public-005564 Accessed online 17th July 2019.

Saraux, A., Hudry, C., Zinovieva, E., Herman-Demars, H., & SELF-I Investigators group (2019). Use of auto-injector for methotrexate subcutaneous self-injections: High satisfaction level and good compliance in SELF-I study, a randomized, open-label, parallel group study. Rheumatology and Therapy, 6, 47–60. https://doi.org/10.1007/s40744-018-0134-2

Scott, D. G., Claydon, P., & Ellis, C. (2014). Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: The MENTOR study, Scandinavian Journal of Rheumatology, 43(6), 470–476. https://doi.org/10.3109/03009742.2014.910312

Smolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., ... van der Heijde, D. (2010). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 69(6), 964–975. https://doi.org/10.1136/annrheumdis-2013-204573

Thakur, K., Biberger, A., Handrich, A., & Farouk Rezk, M. (2016). Patient perceptions and preferences of two etanercept autoinjectors for rheumatoid arthritis: Findings from a patient survey in Europe. Rheumatology and Therapy, 3, 245–256. https://doi.org/10.1007/s40474-016-0048-9

Vena, G. A., Cassano, N., & Lannone, F. (2018). Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. Therapeutics and Clinical Risk Management, 14, 105–116. https://doi.org/10.2147/TCRM.S154745

How to cite this article: Homer D. Using video-based training for button-free auto-injection of subcutaneous methotrexate: A pilot study. Musculoskeletal Care. 2019;17:274-279. https://doi.org/10.1002/msc.1420